'Progression free survival' diaporamas de présentation

Management of Advanced Pancreatic Cancer

Management of Advanced Pancreatic Cancer. Wenqing Zhang, MD Medical Oncology/Hematology Fellow James Graham Brown Cancer Cancer University of Louisville Multimodality Meeting 3/4/10. INTRODUCTION. CA Cancer J Clin. 2008 Mar-Apr;58(2):71-96. Epub 2008 Feb 20.

925 views • 71 slides

1.06k views • 55 slides

Chronic Leukemias

Chronic Leukemias. Chronic Leukemias. CLL CML CMML. Normal CBC with lymphocyte. Chronic Leukemias. CLL CML CMML. Chronic Leukemias. CLL- Chronic Lymphocytic CML CMML. Chronic Leukemias. CLL incidence 4:100,000 Male to Female 2:1 age <65 Mean age 72 Less than 3% in age <45

740 views • 54 slides

794 views • 53 slides

1.38k views • 50 slides

Non-surgical Treatment of Diffuse Malignant M esothelioma

Non-surgical Treatment of Diffuse Malignant M esothelioma. G u nt u l u Ak , MD Eski s ehir Osmangazi University Medical Faculty Department of Pulmonary Medicine. Conflict of interest statement. None. Contents. Chemotherapy First-line chemotherapy Second-line chemotherapy

647 views • 50 slides

Keith T. Flaherty, MD Assistant Professor of Medicine Abramson Cancer Center of the

Clinical Updates Novel Agents for the Treatment of Metastatic Melanoma Future Directions: Opportunities for Targeting B-RAF and Other Targets in Melanoma Management. Keith T. Flaherty, MD Assistant Professor of Medicine Abramson Cancer Center of the University of Pennsylvania

598 views • 42 slides

At initial diagnosis

1. In general, when do you typically order mutation testing for your patients with newly diagnosed ovarian cancer?. Medical Oncologists. Gynecologic Oncologists. 12. 12. At initial diagnosis. 0. 0. At first relapse. 0. 0. At second relapse.

885 views • 37 slides

Intraperitoneal Cisplatin and Paclitaxel in Ovarian Cancer

Intraperitoneal Cisplatin and Paclitaxel in Ovarian Cancer. ????? ???? R2 ???. BACKGROUND. Ovarian cancer - leading cause of the death in USA Standard chemotherapy for the initial Tx - combination of a platinum analogue with paclitaxel - with modern surgical intervention

565 views • 29 slides

NCIC CTG CO.17 Abstract Authors

A trial of the National Cancer Institute of Canada Clinical Trials Group (NCIC CTG) and the Australasian Gastro-Intestinal Trials Group (AGITG).

572 views • 28 slides

E1496: ECOG and CALGB

E1496: ECOG and CALGB. Cyclophosphamide/Fludarabine (CF) with or without Maintenance Rituximab (MR) in Advanced Indolent Lymphoma Patients: Results from the E1496 Trial Howard S. Hochster Edie Weller Randy D. Gascoyne Theresa S. Ryan Thomas M. Habermann Leo I. Gordon Stanley R. Frankel

538 views • 26 slides

780 views • 21 slides

FIRIS study

A Phase III trial of 5-FU/ l -leucovorin/ irinotecan ( F OLFIRI) versus irinotecan/S-1 ( IRIS ) as second-line chemotherapy for metastatic colorectal cancer.

306 views • 16 slides

9/30/10

ACRIN 6682 Phase II Trial of 64 Cu-ATSM PET/CT in Cervical Cancer Principal Investigator: Farrokh Dehdashti, MD. 9/30/10. Background. Tumor hypoxia is an important prognostic factor in cervical cancer and predicts for decreased overall and disease-free survival

205 views • 13 slides

10/2/09

ACRIN 6682 Phase II Trial of 64 Cu-ATSM PET/CT in Cervical Cancer Principal Investigator: Farrokh Dehdashti, MD. 10/2/09. Background. Tumor hypoxia is an important prognostic factor in cervical cancer and predicts for decreased overall and disease-free survival

406 views • 12 slides

10/2/09

ACRIN 6682 Phase II Trial of 64 Cu-ATSM PET/CT in Cervical Cancer Principal Investigator: Farrokh Dehdashti, MD. 10/2/09. Background. Tumor hypoxia is an important prognostic factor in cervical cancer and predicts for decreased overall and disease-free survival

228 views • 12 slides

Kristensen G et al. Proc ASCO 2011;Abstract LBA5006.

Result of Interim Analysis of Overall Survival in the GCIG ICON7 Phase III Randomized Trial of Bevacizumab in Women with Newly Diagnosed Ovarian Cancer. Kristensen G et al. Proc ASCO 2011;Abstract LBA5006. Background.

182 views • 6 slides

Cycles of PLD/Carboplatin Received (n=58)

Cycles of PLD/Carboplatin Received (n=58). Adapted from: ESGO 2007, Berlin. Progression-free Survival* (n=58). 100%. Time to progression (months) Median (10.5) Maximum (22.5) Minimum (1.6). 80%. 60%. Patients (%). 40%. 20%. 0%. Months. 0. 3. 6. 9. 12. 15. 18. 21. 24.

154 views • 3 slides

Overall Survival and Progression-Free Survival

Overall Survival and Progression-Free Survival.

371 views • 1 slides

Clinical outcome in patients with metastatic colorectal cancer harboring KRAS p.G13D mutation treated with Cetuximab GI-biomarker 0902. Enrollment: 94. SD. PD. PR.

141 views • 1 slides